(MedPage Today) — You passed medical training, now see if you can pass our weekly quiz

Use of GLP-1 receptor agonist medications (GLP-1s) has skyrocketed in recent years, and many people are using “compounded” GLP-1 products: medicines that include GLP-1s as well as other active substances, some of which are not regulated by the FDA. A new study found that compounded GLP-1s now make up a large majority of weight-loss medicines, commonly containing vitamin B12 analogs that have not been tested for safety in combination with GLP-1s.

Saturday, November 14 – ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment.

Saturday, November 14 – A study of more than 750,000 pregnancies found that early exposure to Ozempic, Wegovy, and similar drugs was not linked to increased pregnancy complications when used for weight loss, but was associated with a higher risk of premature birth when prescribed for diabetes. The surprising difference suggests that diabetes itself may be driving the risk, although researchers caution that the drugs’ safety during pregnancy remains uncertain.

Saturday, November 14 – China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.

Saturday, November 14 – (MedPage Today) — The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM…

Saturday, November 14 – Up to $1.5 billion from Blackstone Life Sciences for Pfizer Inc.’s push with GLP-1 prospect berobenatide (bero) will also help with the looming patent cliff, too, as the pharma giant faces loss of exclusivity for factor Xa inhibitor anticoagulant Eliquis (apixaban) in the spring of 2028.

Friday, November 13 – Thinking of quitting a GLP-1? A physician outlines six risks, from weight regain and muscle loss to worsening biomarkers and mental health consequences.

Friday, November 13 – (MedPage Today) — Liver transplant patients who took a GLP-1 receptor agonist had a lower risk of death than those who weren’t on a GLP-1 drug, according to a retrospective three-center cohort study.
Among 2,402 patients, those on GLP-1 receptor…

Friday, November 13 – (MedPage Today) — Survodutide, an investigational glucagon receptor and GLP-1 receptor dual agonist, was safe for patients with obesity and either established cardiovascular disease (CVD), chronic kidney disease (CKD), or increased risk of CVD…

Thursday, November 12 – A rare eye disease has been added to the growing list of side effects linked to GLP-1s, adding a second eye warning to several labels. Michael Siluk/UCG/Universal Images Group via Getty Images

The FDA is requiring new warnings on Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1s about a potential increase in the risk of a rare eye condition that can cause sudden vision loss.

Regulators in the European Union, United Kingdom, and Australia have added similar warnings, mostly for semaglutide.

Thursday, November 12 – Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.

Thursday, November 12 – (MedPage Today) — The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, two phase III trials showed.
For the treatment…

Thursday, November 12 – Adults with moderate-to-severe sleep apnea and excess weight had significantly fewer episodes of breathing interruptions while sleeping after taking the daily oral GLP-1 medication orforglipron for one year, compared with adults in the placebo group, according to new, independent, preliminary late-breaking science presented Monday at the American Heart Association’s Scientific Sessions 2026 in Chicago.

Thursday, November 12 – A study has revealed that resistance (weight) training not only preserves lean and muscle mass but also increases strength in people taking weight-loss medication. Published in Nature Medicine, the Tirzepatide and Resistance Exercise (T-REx) study is the first to show the effects of combining a GLP-1 medicine and resistance training on body composition, muscle mass, strength and a range of cardiovascular health measures.

Thursday, November 12 – A former Eli Lilly sales rep filed a lawsuit alleging she was fired after claiming the company was inappropriately promoting its Mounjaro diabetes drug to combat weight loss.

Thursday, November 12 – The FDA warned that GLP-1 drugs carry a potential risk of a rare but serious eye condition sometimes referred to as an “eye stroke.”

Thursday, November 12 – The FDA approved a novel drug to reduce recurrence of stroke, the agency is warning that GLP-1s carry a potential risk for an eye condition, and more pharma news of…

Tuesday, November 11 – They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted kilograms. But while medications such as Ozempic and Wegovy may also improve women’s chances of becoming pregnant, what happens to their unborn babies if they continue to take the drugs during pregnancy?

Tuesday, November 11 – There’s a new alert on those popular GLP-1 weight loss drugs. The FDA is now mandating a warning label that the drugs may cause sudden blindness. NBC News’ Stephanie Gosk reports. 

Tuesday, November 11 – The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with popular drugs used for weight loss and diabetes, such as Ozempic

Tuesday, November 11 – A former pharmaceutical sales representative on Monday told a Texas federal court that Eli Lilly and Co. wrongfully fired her after she blew the whistle on the company’s practice of offering its lucrative drug Mounjaro as a weight loss drug, saying Eli Lilly asked her to breach the law.

Tuesday, November 11 – Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.

Tuesday, November 11 – Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs and the onset of cancers in people with diabetes.

Tuesday, November 11 – GLP-1 drugs may increase the risk of NAION, a rare optic nerve condition that can lead to sudden vision loss. It has no known treatment.

Tuesday, November 11 – The U.S. Food and Drug Administration on Monday said it is requiring new warnings on GLP-1 medications, the group of blockbuster drugs prescribed for diabetes and weight loss, for a serious, rare condition that can cause sudden and possibly permanent vision loss in one eye.

Tuesday, November 11 – (MedPage Today) — The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding…

Tuesday, November 11 – A rare risk of vision loss and the potential for malignancies are on the U.S. FDA’s radar as it orders a new safety warning for GLP-1 drugs and investigates the risk of neoplasia with Novartis AG’s Zolgensma and Itvisma, both of which are onasemnogene abeparvovec products indicated for spinal muscular atrophy.

Tuesday, November 11 – The FDA on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition that’s sometimes referred to as an “eye stroke.”

Tuesday, November 11 – Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in two late-stage studies, but it doesn’t appear as effective as Lilly’s injectable drug Zepbound.

Monday, November 9 – Gary Brecka says just six minutes of daily resistance training can help protect lean body mass during Ozempic and Wegovy weight loss journeys.

Monday, November 9 – (MedPage Today) — ORLANDO — The investigational obesity drug retatrutide was highly effective in reducing pain and improving disability in knee osteoarthritis (OA) associated with obesity, according to the TRIUMPH-4 trial.
Among patients in…

Sunday, November 8 – (MedPage Today) — A few clicks, a credit card, and a package arrives at your door. The same technology that has expanded access to information and consumer goods has also made it easier than ever for unregulated products to reach consumers while…

Saturday, November 7 – Bariatric surgery is associated with clinically meaningful two-year weight loss after semaglutide or tirzepatide intolerance or inadequate response, according to a study published online Nov. 3 in the Annals of Surgery.

Friday, November 6 – (MedPage Today) — Diabetic patients treated with GLP-1 receptor agonists had a lower cancer risk versus insulin and sulfonylureas but not other diabetes medications, although the benefits varied by diabetes severity, a large cohort analysis with…

Thursday, November 5 – With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.

Thursday, November 5 – A new tablet version of Wegovy, a peptide used to help people lose weight, has been approved for the first time in Australia.

Thursday, November 5 – Novo CEO Mike Maziar Doustdar insists that his company is ahead of fierce rival Eli Lilly as oral Wegovy rises to 8 million total prescriptions since its January launch.

Wednesday, November 4 – GLP-1 drugs like Ozempic and Mounjaro treated prediabetes more effectively than metformin, according to a new study. Milko/E+/Getty Images

Researchers say GLP-1 medications appear to be more effective in treating prediabetes than the commonly prescribed drug metformin.

They said GLP-1 drugs were also associated with a lower risk of developing type 2 diabetes as well as fewer cases of heart attack and stroke.

Tuesday, November 3 – Stanford researchers have discovered an AI-identified natural molecule that dramatically suppresses appetite and promotes fat loss in animals, potentially offering an Ozempic-like weight-loss treatment without common digestive side effects or significant muscle loss. Called BRP, the molecule reduced food intake by up to 50% and targets a different brain pathway, raising hopes for a more precise obesity treatment if future human trials prove successful.